Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2368240
Max Phase: Preclinical
Molecular Formula: C52H76O17
Molecular Weight: 973.16
Molecule Type: Small molecule
Associated Items:
ID: ALA2368240
Max Phase: Preclinical
Molecular Formula: C52H76O17
Molecular Weight: 973.16
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC[C@H](C)[C@H]1O[C@]2(C=C[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@@H](OC)[C@@H](O[C@H]4C[C@@H](OC)[C@@H](OC(=O)CCC(=O)O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2
Standard InChI: InChI=1S/C52H76O17/c1-11-27(2)46-30(5)19-20-51(69-46)25-36-22-35(68-51)16-15-29(4)45(28(3)13-12-14-34-26-61-49-44(56)31(6)21-37(50(57)64-36)52(34,49)58)66-42-24-39(60-10)48(33(8)63-42)67-43-23-38(59-9)47(32(7)62-43)65-41(55)18-17-40(53)54/h12-15,19-21,27-28,30,32-33,35-39,42-49,56,58H,11,16-18,22-26H2,1-10H3,(H,53,54)/b13-12+,29-15+,34-14+/t27-,28-,30-,32-,33-,35+,36-,37-,38+,39+,42-,43-,44+,45-,46+,47-,48-,49+,51+,52+/m0/s1
Standard InChI Key: MESYMBMWAHSLQZ-MBMVUBOVSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 973.16 | Molecular Weight (Monoisotopic): 972.5083 | AlogP: 5.79 | #Rotatable Bonds: 12 |
Polar Surface Area: 213.43 | Molecular Species: ACID | HBA: 16 | HBD: 3 |
#RO5 Violations: 3 | HBA (Lipinski): 17 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 4.04 | CX Basic pKa: | CX LogP: 6.11 | CX LogD: 2.98 |
Aromatic Rings: 0 | Heavy Atoms: 69 | QED Weighted: 0.16 | Np Likeness Score: 2.14 |
1. Mrozik H, Eskola P, Fisher MH, Egerton JR, Cifelli S, Ostlind DA.. (1982) Avermectin acyl derivatives with anthelmintic activity., 25 (6): [PMID:7097720] [10.1021/jm00348a010] |
Source(1):